MYOG Myogen

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that J. William Freytag, President and CEO, will present a corporate overview at the UBS Global Life Sciences Conference to be held Sept. 25-28, 2006, at the Grand Hyatt Hotel in New York City. The presentation will take place at 8:30 a.m. (EST) on Wednesday, Sept. 27, 2006. There will be a live webcast of the presentation, which will be accessible through a link posted on the investor relations section of the Myogen website at http://investor.myogen.com/. The webcast will be available for replay on Myogen's website through Oct. 11, 2006. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension. Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for Injection in the United States and GlaxoSmithKline has licensed ambrisentan from Myogen for all territories outside of the United States, where Myogen retains exclusive rights. Myogen also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com. Safe Harbor Statement The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended Dec. 31, 2005, and Myogen's periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.